{"id":"W4385989336","doi":"10.1016/j.annonc.2023.08.003","title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Principia Biopharma; ImmunoMedics; Sierra Oncology; Loxo Oncology; Chugai Pharmaceutical; AstraZeneca; Genentech; Amgen; Science Foundation Ireland; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; FibroGen; Puma Biotechnology; Novartis Pharmaceuticals Corporation; F-star Therapeutics; Aminex Therapeutics; F. Hoffmann-La Roche; Genomic Health; Menarini Silicon Biosystems; BeiGene; University of Wisconsin Carbone Cancer Center; Sun Pharma; Five Prime Therapeutics; Array BioPharma; Merck KGaA; Memorial Sloan-Kettering Cancer Center; National Institutes of Health; Natera; BioMarin Pharmaceutical; Astellas Pharma; Eisai; Daiichi Sankyo Europe; University of Wisconsin-Madison; National Breast Cancer Foundation; Incyte; Servier; Gilead Sciences; Exelixis; Jounce Therapeutics; Breast Cancer Research Foundation; Apollomics; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer","keywords":"Fulvestrant; Neratinib; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Breast cancer; Cancer; Gastroenterology; Progressive disease; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002284253,0.001681936,0.002175798,0.0002719546,0.0004274032,0.00133887,0.0006813282,0.0007454623,0.002287639],"category_scores_gemma":[0.001808146,0.0002882839,0.002322012,0.0004963162,0.0007463699,0.001605671,0.0007641289,0.001899869,0.0006584966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001274166,"about_ca_system_score_gemma":0.0009154807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001223497,"about_ca_topic_score_gemma":0.004701576,"domain_scores_codex":[0.9993117,0.0003013978,0.00004081158,0.0001248113,0.00008991294,0.0001313062],"domain_scores_gemma":[0.9993315,0.0001327115,0.000202114,0.00007246043,0.00005881812,0.000202317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8289569,0.00409369,0.02949513,0.002219271,0.01188443,0.0002807661,0.0002469032,0.005654261,0.006388727,0.0008692949,0.0179557,0.09195483],"study_design_scores_gemma":[0.5913988,0.1466435,0.1938606,0.0006319741,0.02190488,0.001461006,0.0005728544,0.006157899,0.004731997,0.003950327,0.02839999,0.0002861426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806374,0.008689651,0.0002657062,0.001559046,0.0002395843,0.0003158512,0.004888617,0.00006922377,0.003334947],"genre_scores_gemma":[0.981455,0.003082918,0.0005101016,0.001244718,0.0003589471,0.000568523,0.01021535,0.00003284297,0.002531529],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002287639,"threshold_uncertainty_score":0.01208043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09886301706774538,"score_gpt":0.4203931923658902,"score_spread":0.3215301752981448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}